Dr Doris Hansen speaks to ecancer about a study presented at ASH 2024 which evaluated the safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in relapsed/refractory multiple myeloma (RRMM).

It analyses data from 641 patients, focusing on the outcomes of those infused with ciltacabtagene autoleucel and idecabtagene vicleucel.

Results show that while ciltacabtagene autoleucel was associated with higher risks of severe side effects, it also showed better response rates and significantly superior survival compared with idecabtagene vicleucel.